Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
The honeymoon is over. After years of intensive study, cancer researchers are no longer making glowing predictions about interferon's anticancer effects. Instead, new data from a number of phase II clinical trials indicate that large doses of pure interferon produced by genetic engineering techniques have only limited effects against some tumor types and no effect against others. Such studies have also confirmed that the most commonly tested subtype of interferon is inherently toxic, causing side effects in patients that range from mild to life-threatening. A number of reports were presented at the recent tandem meetings of the American Society of Clinical Oncology and the American Association for Cancer Research in San Diego. Several concerned two leukocyte interferons [IFN-α] produced with recombinant DNA technology. One is rIFN-αA, distributed by Hoffmann-LaRoche, Inc, Nutley, NJ, and the other is rIFN-α2, from Schering-Plough Corporation, Kenilworth, NJ. The two molecules are essentially the same—differing only
JAMA – American Medical Association
Published: Aug 26, 1983
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.